ALIM Alimera Sciences Inc: Enterprise Value to EBITDA Ratio

The EV/EBITDA price chart for Alimera Sciences (ALIM), which specializes in ophthalmology products, is currently at . Alimera Sciences (ALIM) dominates pricing power thanks to its innovative Iluvien implant, which provides three-year retinal therapy. However, geopolitical tensions and sanctions are limiting exports and disrupting supply chains. The business's environmental focus is centered on upgrading packaging and optimizing temperature-controlled transport via contractors.

Alimera Sciences Inc - ALIM Company Value to EBITDA (period 07/04/2022 - 11/12/2026)

Metric breakdowns and analytics for alimerasciences.com (ALIM)

- current price and projected stock value:

Stock Price Alimera Sciences, Inc.|ALIM - Average Forecast Price

- company stock capitalization data:

Market Valuation ALIM|ALIM - Total Enterprise Value

- business book valuation details:

Book Value per Share Alimera Sciences|ALIM - Total Stockholders' Equity|Market Value to Book Value Ratio alimerasciences.com|ALIM - Company Total Asset Base

- debt and liquidity data:

- financial results and valuation multiples details:

ALIM - Company Net Income|Expected Profit Alimera Sciences|ALIM - Company Value to Net Income|Forward P/E Multiple Alimera Sciences, Inc.|ALIM - PEG Multiple|Enterprise Value to EBITDA Ratio ALIM|ALIM - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Alimera Sciences|ALIM - Net earnings per share for the last four quarters|Quarterly EPS earnings growth alimerasciences.com|ALIM - Net earnings per share growth this year|Earnings growth forecast for next year Alimera Sciences

Summary company analytics:Alimera ALIM

Product sample of Alimera Sciences, Inc.

Steady demand for chronic retinal disease therapies generates a consistent cash flow for Alimera Sciences (ALIM). By analyzing the EV/EBITDA ratio from a historical perspective, an investor compares the enterprise value of the business with its operating profit before interest and taxes. This metric allows for an assessment of the real value of assets relative to their ability to act as a cash generator, excluding the impact of debt load and inflationary costs.

Analysis of competing companies

EV/EBITDA Multiple ALC (Alcon Vision)|Bausch Health (BLCO) - Company Value to EBITDA|GKOS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA apellis.com|BLTE: EV/EBITDA Multiple|Company Value to EBITDA Ocular Therapeutix Inc (OCUL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harrow Health|Viridian Corp (VRDN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple LENZ|EV/EBITDA Multiple Oculis Holding AG (OCS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization EyePoint Pharmaceuticals, Inc. EYPT|Kodiak Sciences Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Aldeyra - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio KALA BIO, Inc. KALA|opusgtx.com (IRD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio OKYO Pharma|ADVM (Adverum Biotechnologies Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Outlook Therapeutics Inc OTLK|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clearside (CLSD)|NBY (novabay.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KPRX (Kiora Pharmaceuticals, Inc.)|EV/EBITDA Multiple Eyenovia Inc. EYEN|GHSI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation OCUP (Ocuphire Pharma Inc)|Opthea Ltd. (OPT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization